Research Study: Randomized Open-Label Phase 3 Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC)

Dr. Linda Vahdat is seeking women 18 years of age or older, diagnosed with metastatic triple negative breast cancer for a research study.

This clinical trial is for women with metastatic triple negative breast cancer (mTNBC). This means that the three most common types of receptors (estrogen, progesterone, and human epidermal growth factor [HER2]) known to fuel most breast cancer growth are not present in their cancer.

To learn more about the study and to see if you are eligible [go]

Leave a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s